Quark, Nitto Denko collaborate on fibrotic diseases

Quark Pharmaceuticals, a Fremont, CA-based developer of RNAi-based therapeutics, is collaborating with Nitto Denko, a diversified materials manufacturer based in Osaka, Japan, to develop siRNA therapeutics to treat fibrotic diseases. Quark will provide the RNAi technology and Nitto Denko will work on drug delivery. The two companies are aiming for an Investigational New Drug designation by the FDA by early 2012. Release